临床药物遗传学检测与应用:韩国检验医学会2024年更新指南
该指南由韩国检验医学会更新,针对药物遗传学临床实施受限的现状,系统整理了命名、基因-药物关系、基因分型技术、检测策略、临床信息传递、质量控制及报销等知识,旨在为计划开展或扩展药物遗传学检测的临床实验室提供必要信息。
要点
- 临床实验室在药物遗传学及时落地中起关键作用
- 指南涵盖基因分型技术、检测策略与质量控制
- 提供临床相关信息传递及报销等实施要点
核心结论
- 临床实验室是推动药物遗传学检测及时临床应用的关键环节。
研究设计与样本
- 韩国检验医学会发布的临床药物遗传学检测与应用指南更新版。
主要发现
- 多数国家包括韩国的药物遗传学临床实施仍限于少数基因-药物组合。
- 实施延迟主因是基因分型技术挑战与医疗提供者知识缺口。
临床怎么用
- 为计划实施或扩展药物遗传学检测的临床实验室提供所需信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the era of precision medicine, pharmacogenetics has substantial potential for addressing inter-individual variability in drug responses. Although pharmacogenetics has been a research focus for many years, resulting in the establishment of several formal guidelines, its clinical implementation remains limited to several gene-drug combinations in most countries, including Korea. The main causes of delayed implementation are technical challenges in genotyping and knowledge gaps among healthcare providers; therefore, clinical laboratories play a critical role in the timely implementation of pharmacogenetics. This paper presents an update of the Clinical Pharmacogenetic Testing and Application guidelines issued by the Korean Society for Laboratory Medicine and aims to provide the necessary information for clinical laboratories planning to implement or expand their pharmacogenetic testing. Current knowledge regarding nomenclature, gene-drug relationships, genotyping technologies, testing strategies, methods for clinically relevant information delivery, QC, and reimbursements has been curated and described in this guideline.
引用
- Rim JH, Kim YG, Kim S, et al. Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine. Ann Lab Med. 2024. PMID: 39681357. doi:10.3343/alm.2024.0572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。